Atsena Therapeutics

??BREAKING?? The #FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis. Read more: #OcularSurgeryNews #Retina Atsena Therapeutics Kenji Fujita https://lnkd.in/eV6qC8bQ

Exciting news! The FDA has granted Fast Track designation to ATSN-201, our investigational #GeneTherapy for X-linked retinoschisis (#XLRS)—marking its third FDA designation alongside?Orphan Drug and Rare Pediatric Disease status. ? ATSN-201 leverages our AAV.SPR spreading capsid to achieve therapeutic gene expression without the surgical risks of foveal detachment. This designation reinforces its potential?to address the significant unmet need in XLRS. ? Learn more: https://lnkd.in/e_3X2VHf ? Visual description: ? The image features a headshot of Atsena Therapeutics CEO Patrick Ritschel. On the right, a quote from him appears in white text on a purple and blue gradient background, announcing?the FDA’s Fast Track designation for ATSN-201. The Atsena logo is in the bottom right corner.

ICYMI: Atsena Therapeutics is Seeking Insights from the XLRS Community! We’re conducting a survey for individuals diagnosed with X-linked retinoschisis (#XLRS) and their caregivers to better understand how XLRS impacts daily life. Your experiences are critical in helping us advance our mission to improve lives through innovative gene therapies. As a thank you, we will contribute to a charitable organization supporting individuals with visual impairments for every completed survey. If you or someone you know is living with or caring for someone with XLRS, please consider participating and sharing this opportunity. Follow the link below to take the survey!?https://lnkd.in/g-i6TmEd ? Visual description: On the right of the image, a circular cutout contains a photo of a smiling family—a young boy playing with a red ball while his parents sit on a gray couch. The text on the left in bold and regular fonts asks if the viewer or a loved one has X-linked retinoschisis, followed by an orange call-to-action button that says, "We want to hear from you!"

#DYK: There are more than 6,000 identified rare diseases and more than 70% of rare diseases are genetic. ? Rare diseases, including X-linked retinoschisis (#XLRS) and Leber congenital amaurosis (LCA), often lack effective treatments, but through innovation and collaboration, we are working to change that. At Atsena, we are dedicated to advancing #GeneTherapy treatments for these #InheritedRetinalDiseases, to restore or preserve vision for those affected. ? We stand with patients, families, and the rare disease community today and every day. ? #RareDiseaseDay #RareButStrong ? Visual description: A colorful background features the Rare Disease Day logo in the top left and the Atsena logo in the top right. The central text reads, 'ATSENA SUPPORTS RARE DISEASE DAY' with the date '28 FEB 2025' and the hashtag '#RareDiseaseDay.' A pink banner at the bottom says 'LEARN MORE ON' with a link to?rarediseaseday.org.

February is Low Vision Awareness Month, a time to recognize the millions affected by vision impairment and highlight the importance of research and innovation in ophthalmology.?Learn more about Low Vision Awareness Month from the National Eye Institute (NEI) here: https://lnkd.in/er2bvAZi. ? By harnessing cutting-edge science, Atsena is advancing?#GeneTherapies?that have the potential to restore or preserve sight for individuals with #InheritedRetinalDiseases.? ? #LowVisionAwarenessMonth? ? Visual description: ? The left side of the image has a solid dark blue background with white and orange text. At the top, inside an orange rounded shape, the text reads: "FEBRUARY IS". Below this, in large white capital letters, the main message states: "LOW VISION AWARENESS MONTH". ? At the bottom left corner, the Atsena logo is displayed. The logo consists of a stylized "A" with a blue, orange, and purple gradient, alongside the company’s name in white text. On the right side of the image, there is a photograph of an elderly woman undergoing an eye exam. A male eye doctor is wearing a white coat and is examining her eyes through the equipment. The background of the photograph is neutral beige. ? A curved, wave-like design in white and light blue separates the dark blue text area from the photograph, creating a visually appealing transition between the two sections.

Do you or does someone you know have a connection to X-linked retinoschisis (#XLRS)? Atsena Therapeutics wants to hear from you! We’re conducting a survey for individuals diagnosed with XLRS and their caregivers to better understand how XLRS impacts daily life. As a thank you, we will contribute to a charitable organization supporting individuals with visual impairments for every completed survey. Understanding the XLRS community's perspective is critical for advancing our mission of improving lives through innovative gene therapies. Please share this survey opportunity with those who may be living with or caring for someone with XLRS. Follow the link below to participate in the survey. ? https://lnkd.in/g-i6TmEd ? Visual description: The Atsena Therapeutics logo is positioned at the top left, featuring a colorful abstract design in orange, purple, and teal. Large, bold text in purple reads: "Have you or someone you know been diagnosed with X-linked retinoschisis?" Below this, in an orange rounded rectangle, white text states: "We want to hear from you!" ? A close-up image of a young child’s eyes is positioned on the right side, framed by a circular orange border. The child’s gaze is focused, and the photo emphasizes their eyelashes and eyebrows. The background features a soft white dotted pattern with purple and orange design accents framing the edges.

We’re thrilled to announce that safety and efficacy #data on ATSN-201 for X-linked retinoschisis (#XLRS) will be presented at The Macula Society’s 48th Annual Meeting on February 12-15, 2025, in Charlotte Harbor, FL. ATSN-201, powered by our novel AAV.SPR spreading capsid, is designed to deliver best-in-class #GeneTherapy without the surgical risks of foveal detachment. #MaculaSociety2025 ? ???Session:?Inherited Retinal Dystrophy I: Trials ???Date & Time:?Feb. 13, 2025, 7:00-7:45 a.m. ET ???Presentation:?Interim Safety & Efficacy of ATSN-201 ?????Presenter:?Christine Nichols Kay, MD ? Visual description: The background transitions from dark purple at the top to blue at the bottom. At the top, there is a bold orange banner with white text stating, "WE’RE PRESENTING AT".? ? Below this, in large white and light blue text, the main event title reads, "The Macula Society 2025 Annual Meeting". ? Below the event title, the date and time are displayed in white and yellow text: "FEB. 13, 2025, 7:00-7:45 A.M. ET" The presentation topic is in italicized white text: "Interim Safety & Efficacy of ATSN-201" and the session name follows: "Inherited Retinal Dystrophy I: Trials" ? On the right side of the image, there is a circular, professional headshot of Christine Nichols Kay, MD. Her name is written in white text inside an orange rounded rectangle below her image. At the bottom right corner, the Atsena logo is displayed, consisting of a stylized "A" with blue, orange, and purple gradient colors, accompanied by the company's name in dark blue text. https://lnkd.in/eP9NGfrj

Braille is a vital tool for independence, communication, and access to education for individuals who are blind or have low vision. As we work toward creating life-changing gene therapies for #InheritedRetinalDiseases, we are reminded of the importance of inclusive innovations and accessibility. Braille has empowered millions worldwide, and we’re inspired by its legacy as we strive to make a meaningful impact in the lives of those living with vision loss. ? Visual description: On the left side, large white text on a purple gradient background reads: "January is Braille Literacy Month." The logo for "Atsena Therapeutics" appears in the bottom-left corner. On the right side of the image, there is a photograph of a child's hands reading Braille on a tactile page. The child is wearing a light blue sweater, and their fingers are touching the raised Braille dots. A curved orange and blue accent visually separates the text on the left from the photograph on the right.

Atsena’s leadership (Shannon Boye, Kenji Fujita, Patrick Ritschel) attended J.P. Morgan Healthcare Conference (#JPM2025), joining global leaders to discuss advancements shaping the healthcare industry. ? The event captured the importance of collaboration and innovation as we advance #GeneTherapies for #InheritedRetinalDiseases (IRDs). It was a valuable opportunity to share updates on our Phase 1/2 study evaluating a gene therapy for X-linked retinoschisis (#XLRS), our novel platform technologies, and the progress we’ve made on other IRDs with potential partners and investors. ? Visual description: ? This image is a collage showcasing Atsena’s presence at the J.P. Morgan Healthcare Conference. On the left side, the blue background prominently displays the text: “Atsena Therapeutics @ JPM25,” accompanied by the company’s logo, which features a vibrant, abstract design in orange, blue, and teal. ? The right side of the image contains six photos of Atsena's team members in various networking and social settings. The snapshots include: -A group seated around a dining table, smiling and enjoying a meal. -A group of four individuals smiling at the camera in a casual indoor setting. -Five individuals posing together at a professional networking event. -Another group of five attendees, dressed formally, holding glasses at a social gathering. -A trio of people outdoors, smiling against a bustling city street backdrop. -A group shot of individuals, including Atsena team members and others, in a professional environment, holding drinks and mingling. ?

We’re excited to have Kara Fick, our Director of Patient Advocacy and Medical Affairs, represent our team at the Chief Patient Officer Summit West conference to discuss how integrating patient insights can drive meaningful innovation and improve outcomes across the #biopharma industry. We’re committed to patient advocacy and collaboration and look forward to contributing to the dialogue around prioritizing patient needs in ocular #GeneTherapy and beyond. Learn more about the summit here: https://lnkd.in/eSGFTs-q. ? Visual description: The top of the image has text in orange on a purple gradient background which reads "Upcoming Panel Presentation At,” followed by white text: "Chief Patient Officer Summit West." The panel details are in smaller text in white and orange below "WEDS., JAN. 22, 2025 @ 11:15 A.M. PST” “Discover the Patient Perspective on Biopharma Collaboration." There is a circular photo of Kara Fick, with her name listed below in an orange bar. Atsena Therapeutics' logo is positioned at the bottom center.